GILEAD SCIENCES LTD

1. GILEAD SCIENCES LTD 2001-01-02 → present
2. NEXSTAR PHARMACEUTICALS LIMITED 1995-10-27 → 2001-01-02
3. VESTAR LIMITED 1990-11-26 → 1995-10-27
4. MAPLESTORE LIMITED 1990-09-27 → 1990-11-26

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for a period of twelve months from the date of approval of the financial statements. Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.”

Significant events

• “Gilead advanced its leadership in HIV prevention with lenacapavir, a promising twice-yearly injection for PrEP. Named the 2024 Breakthrough of the Year by Science magazine, lenacapavir demonstrated exceptional efficacy in diverse clinical trials.”
• “Beyond HIV, Gilead expanded its oncology portfolio with active Phase 3 trials and cell therapy studies, including Trodelvy® for metastatic breast cancer and anito-cel for multiple myeloma.”
• “Gilead fostered workplace inclusivity through a new Disability Inclusion Employee Resource Group, and continued sustainability efforts by targeting carbon, water, waste, and packaging improvements, remaining on track to achieve 100% renewable electricity by 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +10.1%

  £251,627,000 → £276,958,000

• Cash

  -58%

  £82,659,000 → £34,716,000

• Net assets

  +24.7%

  £30,566,000 → £38,105,000

• Employees

  -3.1%

  195 → 189

• Operating profit

  +9.2%

  £10,100,000 → £11,034,000

• Profit before tax

  +13.5%

  £12,966,000 → £14,714,000

• Wages

  +0.2%

  £25,664,000 → £25,724,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers